DZ-002
/ Da Zen Theranostics
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
September 09, 2025
Groundbreaking Cancer Therapy Advances to Phase 2 Trials
(Bioengineered)
New P2 trial • Oncology
August 23, 2025
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1 | N=14 | Completed | Sponsor: Da Zen Theranostics Inc | Active, not recruiting ➔ Completed
Trial completion • Hematological Malignancies • Lymphoma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor
February 05, 2025
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients with Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1 | N=14 | Active, not recruiting | Sponsor: Da Zen Theranostics Inc | Recruiting ➔ Active, not recruiting | N=55 ➔ 14
Enrollment change • Enrollment closed • Hematological Malignancies • Lymphoma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor
February 19, 2024
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1 | N=55 | Recruiting | Sponsor: Da Zen Theranostics Inc | Trial completion date: Feb 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Jan 2025
Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor
September 11, 2023
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1 | N=55 | Recruiting | Sponsor: Da Zen Theranostics Inc | Trial primary completion date: May 2023 ➔ Dec 2023
Metastases • Trial primary completion date • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Oncology • Prostate Cancer
August 12, 2021
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1; N=55; Recruiting; Sponsor: Da Zen Theranostics Inc; Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor
July 21, 2021
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
(clinicaltrials.gov)
- P1; N=55; Not yet recruiting; Sponsor: Da Zen Theranostics Inc
Clinical • New P1 trial • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor
1 to 7
Of
7
Go to page
1